NCT04578600 2025-04-24CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaUniversity of California, DavisPhase 1 Completed8 enrolled
NCT02343536 2020-08-28A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCelgenePhase 1 Completed59 enrolled